Calcium Carbonate Is an Effective Phosphorus Binder in Children With Chronic Renal Failure

Sharon P. Andreoli, Judith W. Dunson, Jerry M. Bergstein

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

We evaluated the effectiveness of calcium carbonate as a phosphate binder in 19 children with chronic renal failure; ten children were undergoing dialysis therapy (eight maintained by CAPD and two by hemodialysis). Twelve children had previously received aluminum hydroxide, while calcium carbonate was the primary phosphate binder used in seven children. Among all the children, the serum phosphorus level on no phosphate binder was 7.4 ± 0.9 mg/dL, which decreased significantly (P < .001) to 5.9 ± 0.8 mgldL during calcium carbonate therapy, while the serum calcium, bicarbonate, and creatinine were unchanged. The reduction in the serum phosphorus level occurred while dietary intake of calcium and phosphorus were unchanged, as demonstrated by three-day dietary records. The dose of calcium carbonate required to maintain the serum phosphorus in the normal range varied from 600 mg to 15 gld (mean 7.4 gld). Among the 12 children and four others who had received aluminum hydroxide, serum aluminum levels fell from 108.8 ± 121.8 ng/mL to 36.1 ± 29.1 ng/mL after aluminum hydroxide was stopped (P < .05). Serum alkaline phosphatase and parathyroid hormone (PTH) levels during aluminum hydroxide therapy were similar to levels obtained during calcium carbonate therapy, while PTH levels fell in children treated initially with calcium carbonate. All the children have been observed for a mean of 12.0 months (range 4 months to 3 1/2 years). Hypercalcemia occurred in seven children, usually when vitamin D therapy was initiated or the dose changed. Hypercalcemia resolved with adjustment of the vitamin D or calcium carbonate dose in all but one patient. We conclude that calcium carbonate is an effective and safe phosphorus binder in children with chronic renal failure and should replace aluminum hydroxide for this purpose.

Original languageEnglish (US)
Pages (from-to)206-210
Number of pages5
JournalAmerican Journal of Kidney Diseases
Volume9
Issue number3
DOIs
StatePublished - Jan 1 1987

Fingerprint

Calcium Carbonate
Phosphorus
Chronic Kidney Failure
Aluminum Hydroxide
Serum
Phosphates
Hypercalcemia
Parathyroid Hormone
Vitamin D
Dietary Phosphorus
Therapeutics
Diet Records
Dietary Calcium
Continuous Ambulatory Peritoneal Dialysis
Aluminum
Alkaline Phosphatase
Renal Dialysis
Dialysis
Creatinine
Reference Values

Keywords

  • Calcium carbonate
  • aluminum
  • phosphorus
  • renal failure
  • renal osteodystrophy

ASJC Scopus subject areas

  • Nephrology

Cite this

Calcium Carbonate Is an Effective Phosphorus Binder in Children With Chronic Renal Failure. / Andreoli, Sharon P.; Dunson, Judith W.; Bergstein, Jerry M.

In: American Journal of Kidney Diseases, Vol. 9, No. 3, 01.01.1987, p. 206-210.

Research output: Contribution to journalArticle

@article{631430b3a8224a4ea0a8919c9a7d759e,
title = "Calcium Carbonate Is an Effective Phosphorus Binder in Children With Chronic Renal Failure",
abstract = "We evaluated the effectiveness of calcium carbonate as a phosphate binder in 19 children with chronic renal failure; ten children were undergoing dialysis therapy (eight maintained by CAPD and two by hemodialysis). Twelve children had previously received aluminum hydroxide, while calcium carbonate was the primary phosphate binder used in seven children. Among all the children, the serum phosphorus level on no phosphate binder was 7.4 ± 0.9 mg/dL, which decreased significantly (P < .001) to 5.9 ± 0.8 mgldL during calcium carbonate therapy, while the serum calcium, bicarbonate, and creatinine were unchanged. The reduction in the serum phosphorus level occurred while dietary intake of calcium and phosphorus were unchanged, as demonstrated by three-day dietary records. The dose of calcium carbonate required to maintain the serum phosphorus in the normal range varied from 600 mg to 15 gld (mean 7.4 gld). Among the 12 children and four others who had received aluminum hydroxide, serum aluminum levels fell from 108.8 ± 121.8 ng/mL to 36.1 ± 29.1 ng/mL after aluminum hydroxide was stopped (P < .05). Serum alkaline phosphatase and parathyroid hormone (PTH) levels during aluminum hydroxide therapy were similar to levels obtained during calcium carbonate therapy, while PTH levels fell in children treated initially with calcium carbonate. All the children have been observed for a mean of 12.0 months (range 4 months to 3 1/2 years). Hypercalcemia occurred in seven children, usually when vitamin D therapy was initiated or the dose changed. Hypercalcemia resolved with adjustment of the vitamin D or calcium carbonate dose in all but one patient. We conclude that calcium carbonate is an effective and safe phosphorus binder in children with chronic renal failure and should replace aluminum hydroxide for this purpose.",
keywords = "Calcium carbonate, aluminum, phosphorus, renal failure, renal osteodystrophy",
author = "Andreoli, {Sharon P.} and Dunson, {Judith W.} and Bergstein, {Jerry M.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/S0272-6386(87)80056-2",
language = "English (US)",
volume = "9",
pages = "206--210",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Calcium Carbonate Is an Effective Phosphorus Binder in Children With Chronic Renal Failure

AU - Andreoli, Sharon P.

AU - Dunson, Judith W.

AU - Bergstein, Jerry M.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - We evaluated the effectiveness of calcium carbonate as a phosphate binder in 19 children with chronic renal failure; ten children were undergoing dialysis therapy (eight maintained by CAPD and two by hemodialysis). Twelve children had previously received aluminum hydroxide, while calcium carbonate was the primary phosphate binder used in seven children. Among all the children, the serum phosphorus level on no phosphate binder was 7.4 ± 0.9 mg/dL, which decreased significantly (P < .001) to 5.9 ± 0.8 mgldL during calcium carbonate therapy, while the serum calcium, bicarbonate, and creatinine were unchanged. The reduction in the serum phosphorus level occurred while dietary intake of calcium and phosphorus were unchanged, as demonstrated by three-day dietary records. The dose of calcium carbonate required to maintain the serum phosphorus in the normal range varied from 600 mg to 15 gld (mean 7.4 gld). Among the 12 children and four others who had received aluminum hydroxide, serum aluminum levels fell from 108.8 ± 121.8 ng/mL to 36.1 ± 29.1 ng/mL after aluminum hydroxide was stopped (P < .05). Serum alkaline phosphatase and parathyroid hormone (PTH) levels during aluminum hydroxide therapy were similar to levels obtained during calcium carbonate therapy, while PTH levels fell in children treated initially with calcium carbonate. All the children have been observed for a mean of 12.0 months (range 4 months to 3 1/2 years). Hypercalcemia occurred in seven children, usually when vitamin D therapy was initiated or the dose changed. Hypercalcemia resolved with adjustment of the vitamin D or calcium carbonate dose in all but one patient. We conclude that calcium carbonate is an effective and safe phosphorus binder in children with chronic renal failure and should replace aluminum hydroxide for this purpose.

AB - We evaluated the effectiveness of calcium carbonate as a phosphate binder in 19 children with chronic renal failure; ten children were undergoing dialysis therapy (eight maintained by CAPD and two by hemodialysis). Twelve children had previously received aluminum hydroxide, while calcium carbonate was the primary phosphate binder used in seven children. Among all the children, the serum phosphorus level on no phosphate binder was 7.4 ± 0.9 mg/dL, which decreased significantly (P < .001) to 5.9 ± 0.8 mgldL during calcium carbonate therapy, while the serum calcium, bicarbonate, and creatinine were unchanged. The reduction in the serum phosphorus level occurred while dietary intake of calcium and phosphorus were unchanged, as demonstrated by three-day dietary records. The dose of calcium carbonate required to maintain the serum phosphorus in the normal range varied from 600 mg to 15 gld (mean 7.4 gld). Among the 12 children and four others who had received aluminum hydroxide, serum aluminum levels fell from 108.8 ± 121.8 ng/mL to 36.1 ± 29.1 ng/mL after aluminum hydroxide was stopped (P < .05). Serum alkaline phosphatase and parathyroid hormone (PTH) levels during aluminum hydroxide therapy were similar to levels obtained during calcium carbonate therapy, while PTH levels fell in children treated initially with calcium carbonate. All the children have been observed for a mean of 12.0 months (range 4 months to 3 1/2 years). Hypercalcemia occurred in seven children, usually when vitamin D therapy was initiated or the dose changed. Hypercalcemia resolved with adjustment of the vitamin D or calcium carbonate dose in all but one patient. We conclude that calcium carbonate is an effective and safe phosphorus binder in children with chronic renal failure and should replace aluminum hydroxide for this purpose.

KW - Calcium carbonate

KW - aluminum

KW - phosphorus

KW - renal failure

KW - renal osteodystrophy

UR - http://www.scopus.com/inward/record.url?scp=0023215477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023215477&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(87)80056-2

DO - 10.1016/S0272-6386(87)80056-2

M3 - Article

C2 - 3826069

AN - SCOPUS:0023215477

VL - 9

SP - 206

EP - 210

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 3

ER -